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The purpose of this study was to create a thermally stable formulation of 
influenza vaccine that can be delivered intradermally using a microneedle patch. By 
altering drying conditions, storage conditions, and formulation components, vaccine 
activity can be preserved at room temperature for several months in a dried state. 
Delivery via a soluble, biodegradable polymer microneedle patch is the method of choice 
in this study because it allows for self-administration of the drug, creates no sharps waste, 
is pain free, has high bioavailability, and shows potential for removing influenza vaccine 
from cold chain dependency. By optimizing the combination of stabilizing techniques 
previously studied, preliminary results have shown that excipient solutions made up of 
sucrose, trehalose, and arginine, to name a few, in an ammonium acetate buffer are able 
to preserve close to 100% of vaccine activity for at least six months at room temperature 
when patches are loaded with a full human dose. These results show much promise for 










 According to the Centers for Disease Control and Prevention (CDC), influenza is 
a contagious respiratory illness that is spread by a viral vector; however, the CDC also 
states that it is an easily preventable illness if proper immunization is conducted prior to 
being infected [1]. A study conducted by the World Health Organization (WHO) found 
that only 42% of Americans are vaccinated against influenza yearly, and as a result, 
influenza causes close to 4000 (1.2 in every 100,000) American deaths annually. The 
death toll from influenza worldwide is much higher with a range from 250,000 to 
500,000 deaths per year [2]. Getting a simple flu shot significantly decreases the chance of 
contracting the virus and eliminates the chance of death with reasonable statistical 
significance. 
 The most commonly used and traditional method for influenza vaccination today 
is via a syringe fitted with a hypodermic needle. The vaccine used in this method of 
delivery is prepared by reconstituting a lyophilized powder/crystalline form of the 
vaccine. Lyophilization is the process of freeze-drying vaccine in order to make the 
vaccine more thermo-stable and increase its shelf life; however, there are several 
downsides to lyophilization. The major issue is that the powders made by the process 
must still be stored at low temperatures to keep the proteins from denaturing, and thee 
powders are sensitive to changes in humidity. Lyophilized vaccines can also denature 
during the freeze-drying process due to the rapid phase transition to a crystalline form [3].  
 Aside from lyophilization, very little research has been done to find alternative 
methods for delivery of influenza vaccine. At the moment, the major alternative is 
vaccination by nasal mist with parenteral delivery used in extreme cases. Delivery via 
nasal mist is minimally invasive, has a high bioavailability, and is painless and easy to 
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administer, but also has several issues. To name a few limitations, pregnant women, 
patients with lung diseases and asthma, and the elderly may be adversely affected by 
intranasal vaccination [4]. On the other hand, parenteral delivery, which involves 
intravenous (IV) delivery, is able to deliver flu vaccine with the best rate of delivery and 
with instant entry into the bloodstream. The major downside to this method is that the 
patient must be hooked up to an IV and may require local anesthesia in certain cases [5]. 
This method of delivery also bypasses the many antigen presenting cells found in the 
outer tissue layers leading to a decreased immune response. 
 A much better alternative to these methods is to use a soluble, drug loaded, 
microneedle patch. Microneedle patches consist of a small array of soluble needles that 
range anywhere from 50 – 750 microns in length. The stratum corneum is the outer layer 
of skin consisting of dead cells, and drug delivery is impossible if the drug cannot make it 
past this layer. Since the stratum corneum is about 10 – 15 microns in thickness, most 
microneedle patches are easily able to penetrate past this layer of skin. The added benefit 
of this method is that needle length can be targeted to be just enough to reach past the 
stratum corneum, but not any further. This keeps the needles from reaching any nerves in 
the deeper layers (~1 mm is where pain can be felt) of the skin making this method of 
drug delivery completely painless [6]. Also, the microneedles are made of a sugar/polymer 
blend, which dissolves when contacted with skin. The drug is incorporated into the 
microneedles and releases when the needles dissolve into the skin’s interstitial fluid. 
Because the needles are soluble, are so much smaller than syringes, and contain no 
sharps, the amount of waste from delivering drugs through soluble microneedle patches is 
significantly reduced. The lack of pain and the ability to self-administer the patch without 
professional medical assistance also motivates more people to get vaccinated. A study 
found that 7 – 8% of people choose not to vaccinate themselves due to needle phobia [7]. 
Another study found through a survey that offering microneedle patches as an alternative 
to vaccination by syringe increased the number of people who planned on getting their flu 
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shot from 44% to 65% and that 64% of people planning on getting vaccinated would 
have preferred to self administer their vaccination as opposed to going to a healthcare 
center [8]. 
 The one downside to using microneedles as a medium of drug delivery is that they 
can only hold a relatively small volume of drug, and if left at room temperature for more 
than a few minutes, the drug solution will rapidly evaporate. This leads to the aggregation 
of proteins in the vaccine and the resulting conformational change often deactivates or 
damages the proteins to the point where they will no longer be able to elicit an immune 
response. However, there are ways to stabilize the vaccine. Adding excipients to vaccine 
formulations, then drying the vaccine under vacuum or at room temperature (which has to 
be done quickly to prevent denaturation from heat) leads to negligible loss in activity 
when reconstituted. Use of buffer salts, different microneedle materials, varied storage 
temperatures, and several other variables have a wide range of effects on vaccine activity 
while drying, but there are certain combinations of these variables where almost no loss 
of activity occurs. Some excipient stabilizers have even been able to stabilize dried 
vaccines at room temperature for at least one year. This means that the vaccine has the 
potential to be made completely independent of cold chain transport and storage resulting 
in energy savings and increased thermal stability [9]. 
 This study will seek to determine the optimal excipient stabilizers among other 
variables that allow dried influenza vaccine to remain thermally stable and undamaged 
after long-term storage at room temperature. Activity will be tested using enzyme-linked 
immunosorbent assays (ELISAs). If time permits, ELISA data will be supplemented by 
dynamic light scattering (DLS) analysis and circular dichroism (CD) to monitor 
conformational changes. This study will also attempt to conduct an in vivo model in mice 
to ensure that immune response in mice that receive vaccine via microneedle patches is 
not statistically different from those that receive vaccine from a syringe. Long-term goals 
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and implications of this research are to promote and encourage vaccination, pain 






The Influenza Virus 
 Influenza is a seasonal, highly contagious respiratory disease spread that spreads 
as a virus. The main symptoms consist of headaches, high fevers, coughing, and body 
aches to name a few, with death occurring in extreme cases. Death from influenza ranks 
number eight on the Centers for Disease Control and Prevention’s list of most common 
causes of death in the U.S. The virus kills close to 4000 Americans and 250,000 to 
500,000 people around the world each year. Globally, anywhere from 3 – 5 million 
people contract the virus and experience serious illness for some period of time each 
year. Children have a much higher risk of contracting the virus with the attack rate being 
20-30%, yet only 46.9% of American children aged 6 months to 17 years were vaccinated 
in the last year. Adults aged 18-49 have a lower chance of being infected by the virus 
with a chance of 5-10%, yet only 29.6% of American adults are vaccinated against 
influenza annually [2 10 10b]. The easiest way to reduce the risk of death from influenza is 
through immunization two to three weeks prior to “flu season”. A vaccine effectiveness 
study conducted by the CDC shows that getting immunized reduces the risk of 
contracting the virus by 70% on average [11]. Standard flu vaccines are either trivalent or 
quadrivalent, meaning they immunize against three or four strains of influenza 
respectively and are either live attenuated (a deactivated, live virus is introduced to 
promote immunity), or contain pieces of destroyed influenza virus. These strains consist 
of type A and type B strains. The different strains consist of different combinations of the 
two active molecules found on the surface of the influenza virus, hemagglutinin and 
neuraminidase. Hemagglutinin allows the virus to bind and enter cells and neuraminidase 
facilitates exit and spread of the virus to other cells. Vaccination helps promote the 
 6 
creation of antibodies in the blood that are able to recognize and eliminate any virus 
particles with hemagglutinin and neuraminidase on their surface [12]. 
 
Influenza Vaccine 
 Influenza vaccination is currently the only method for significantly reducing the 
chance of contracting the influenza virus; however, the use of vaccine has limitations and 
care must be taken to ensure the sterility and potency of the vaccine. Since the vaccine is 
protein based, it is not very thermo-stable, i.e. it is extremely sensitive to changes in 
temperature. One study found that unaltered influenza vaccine loses almost all of its 
activity after storage at 55°C for three hours. Storage at room temperature increases the 
amount of time it takes the proteins to denature, but in the end, the protein is still 
unusable. The study was able to increase the thermo-stability period by using stabilizers 
in the formulation of the vaccine, but even the most promising of the formulations was 
only able to maintain 50% of its activity after three hours of storage at 55°C. Thermal 
stability in influenza vaccine is usually measured by assaying for hemagglutinin (HA) 
concentration after storage at various conditions [13]. Due to the relative lack of thermal 
stability of influenza vaccine, commercially used influenza vaccine is dependent on the 
cold chain. The CDC recommends that vaccine exposed to temperatures below 2°C or 
above 8°C for longer than a few minutes should not be administered because freezing and 
exposure to high temperatures result in denaturation of the proteins in the vaccine [14]. 
  
Syringe Delivery and Lyophilization 
 In today’s world, hundreds, if not thousands, of drugs, vaccines, individual 
molecules, and various other chemical based compounds have been formulated for 
delivery to the human body, yet only a handful of delivery techniques have been 
researched and developed to facilitate their journey into the body. The vast majority of 
delivery techniques can be categorized into two major groups: invasive and minimally 
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invasive. For influenza vaccine, this narrows down to vaccination by hypodermic syringe 
and needle, intranasal vaccination, parenteral delivery, and transdermal delivery. The 
most common method of delivery by far is via hypodermic needle and syringe. This 
method of delivery relies on using influenza vaccine stored in vials at low temperatures to 
keep the vaccine from denaturing. Currently, very few methods exist to stabilize the 
vaccine at room temperature or higher. The most common method is to lyophilize the 
vaccine after adding excipients and stabilizers. One study tested the effects of freeze-
drying influenza vaccine on vaccine stability after reconstitution and storage at various 
temperatures and found that thermal stability is greatly increased when the vaccine is 
stored as a powder in a sugar glass matrix. Drying of the vaccine reduces the mobility of 
the vaccine making it difficult for the molecules to rearrange and the use of a sugar glass 
matrix keeps the vaccine particles from aggregating; however, the study found that the 
shear stress introduced to the vaccine during freeze-drying resulted in some loss of 
activity and aggregation. The cause of this decrease in activity was most likely due to the 
loss of water, which is necessary to stabilize proteins when in the solid phase, during the 
drying process. The study also tested several other drying methods such as vacuum 
drying, desiccation, and supercritical drying, but many of these methods were unable to 
stabilize the vaccine any better than lyophilization. Also, the study found that most 
lyophilized vaccine powders were rendered completely impotent after storage at 45°C for 
four weeks [15]. Aside from the dependence of the influenza vaccine on the cold chain and 
lyophilization, delivery via hypodermic needle and syringe is also an invasive and painful 
method of drug delivery which results in about 5% of all patient non-compliance for 
vaccination [16]. There is also biohazardous sharps waste that must be properly disposed 





Common Alternatives to Syringe Delivery 
 Aside from delivery via hypodermic needle and syringe, the other two common 
methods of delivering influenza vaccine are via nasal mist and parenteral delivery. 
Intranasal delivery of influenza vaccine is a relatively new method of being immunized 
against influenza and offers several benefits, but also comes with a host of issues. First 
and foremost, intranasal drug delivery offers a much higher bioavailability than 
traditional delivery methods when delivering large molecular weight proteins and 
peptides. This is especially useful when delivering a drug like influenza vaccine because 
the vaccine proteins are live attenuated and mimic the uptake of pathogens through the 
nasal passage as it would occur naturally [17]. This method of drug delivery is also 
painless and is minimally invasive which could result in the decrease of patient non-
compliance. While intranasal delivery of influenza vaccine flaunts high bioavailability 
and the absence of pain, it is not a viable option for everyone in the general population. 
The CDC states that people with respiratory issues, pregnant women, immune-
compromised individuals (vaccine is live attenuated), the elderly, caretakers of immune-
compromised individuals, and individuals that are allergic to eggs are not suitable for 
intranasal vaccination [4]. Intranasal vaccines are formulated in a similar fashion to 
vaccine used in bolus injection, and the FDA states that intranasal flu vaccine must be 
stored at similar conditions to that of regular liquid influenza vaccine. This indicates that 
the thermal stability of intranasal influenza vaccine is not any better than that of standard 
influenza vaccine and will require cold chain storage and transport. Also, the FDA 
regulation for storage of FluMist (one of the more common brands of intranasal influenza 
vaccine) is that the maximum shelf life is 18 weeks when stored between 2 and 8°C [18]. 
The other common (less common than intranasal and syringe) method for influenza 
vaccine delivery is parenteral delivery. Parenteral delivery boasts an almost 100% 
bioavailability and extremely fast delivery speeds since the drug is being inserted directly 
into the bloodstream. It is easy to control dosages and concentrations when delivering via 
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the parenteral route, but that is essentially the only useful attribute. One study found that 
while parenteral influenza vaccination significantly increased immune response and 
antibody levels in the blood and upper respiratory tract, the immune response was 
significantly weaker very shortly after vaccination, with antibody counts back to pre-
vaccination levels after about two to three weeks [5]. Parenteral delivery is also an 
invasive, needle-based method of immunization that requires the patient to be hooked up 
to an IV bag. This method is not only uncomfortable, but is also inconvenient and 
expensive. This method of drug delivery most likely increases patient non-compliance 
even more than needle phobia. Since the vaccine used in parenteral delivery is practically 
the same vaccine used in bolus injection, it is similarly constrained to the cold chain and 
lacks significant thermal stability. 
 
Transdermal Delivery 
 A new and novel approach for the delivery of influenza vaccine is transdermal 
drug delivery. Transdermal drug delivery focuses on delivering drug through the skin as 
the name suggests. There are currently no marketed transdermal influenza vaccinations 
available, but many have shown promise in laboratory and clinical trials. The one major 
barrier to transdermal drug delivery is the fact that only relatively small and hydrophobic 
molecules are easily able to pass through the outmost layer of the skin; however, 
transdermal drug delivery methods have found ways to bypass this outer layer of skin and 
access the underlying aqueous interstitial fluid. Also, because of the large number of 
antigen presenting cells, including Langerhans and dendritic cells present in the skin, 
extremely small doses of vaccine are able to achieve relatively high levels of 
bioavailability. The challenge in drug delivery is being able to get the drug past the 
stratum corneum, as mentioned earlier, which is a layer of dead skin cells just below the 
surface of the skin at the top of the epidermis. Once a drug makes it past the stratum 
corneum, it can be picked up by antigen presenting cells and invoke a cell mediated 
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immune response. Various methods of transdermal delivery have been studied with the 
focus on temporarily disrupting the structure of the stratum corneum in order to allow 
drugs to pass through undisturbed. The major contenders are iontophoresis, ultrasound, 
electroporation, thermal ablation, and microneedle injection. Iontophoresis focuses on 
using an electrical driving force to “push” molecules through the stratum corneum. This 
method has limitations in that it can only achieve high bioavailability for very small 
molecular weight drugs. Ultrasound uses high frequency oscillating pressure waves to 
disrupt the lipid structure of the stratum corneum to create a gap for molecules to pass 
through, but if not properly controlled, can damage lower level tissues in the skin. 
Electroporation uses high voltage pulses to increase cell membrane permeability allowing 
drugs to pass through the stratum corneum in a cell mediated transportation method, but 
engineering of devices to perform this task with proper accuracy is extremely difficult. 
Thermal ablation involves heating a localized area of skin to an extremely high 
temperature within the span of a few milliseconds. The high temperature and short 
duration minimize main and result in small micro craters that allow for enhanced drug 
delivery past the stratum corneum [19]. The aforementioned methods are all novel 
approaches to transdermal drug delivery, but all have major limitations that make it very 
difficult to deliver a drug like influenza vaccine. A much more effective method of 
transdermal drug delivery with less potential for injury is to deliver via a microneedle 
patch. This study will aim to optimize the long-term thermal stability of influenza vaccine 
through transdermal delivery using a soluble microneedle patch. 
 
Microneedles 
 Microneedles injections are made up of an array of micron-sized needles that are 
able to painlessly pierce the outermost layers of the skin and deliver drug past the stratum 
corneum via several different methods. The major classes of microneedles include solid, 
coated, dissolving, and hollow. Solid microneedles create “holes” in the skin that allow 
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for increased delivery upon removal of the needles and secondary application of drug 
formulations. Coated microneedles consist of drug attached to the outside of the needles 
that detach once the needles enter the skin. Dissolving microneedles are fabricated with 
the drug as a part of the needle itself that involves the entire needle dissolving once it 
comes into contact with the skin. Finally, hollow microneedles consist of a backing filled 
with drug that releases through the needles leaving the needles intact upon removal. 
Microneedles are typically made of stainless steel or some form of polymer gel. Each 
type of needle has pros and cons associated with it, but since this study will focus on 
soluble microneedles, they will be discussed in additional detail. 
 
Soluble Microneedles 
 Soluble microneedles are fabricated with water soluble and biodegradable 
polymers that hold the drug within the needles. Once the needle is contacted with the 
skin, the needles begin to dissolve and release the drug. Since the needles are made long 
enough to reach past the stratum corneum, bioavailability is high and most of the drug is 
able to make it past the layer. The needles are also made short enough so that they do not 
interact with pain receptors, which are usually found ~ 1 mm into the skin (well past the 
length of typical microneedles). The advantage of using this method of drug delivery is 
that it is painless and leaves no sharps waste behind. It is also a much easier method of 
drug delivery, potentially allowing for patients to self-administer the vaccine without 
relying on assistance from healthcare professionals [20]. This could lead to decreases in 
patient non-compliance in the future. One study found that offering a self-administrable 
patch for influenza vaccination increased participants’ intent to vaccinate from 44% to 
65% [8].  
 The issue with delivery via soluble microneedles is that the volume of drug is so 
small that it is prone to evaporating very quickly. Once the water has left the surface, the 
influenza vaccine particles begin to aggregate and render the vaccine useless. This means 
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that the thermal stability of unaltered soluble microneedle patches is very low; however, 
this drawback can be remedied. One study dried samples of influenza vaccine under 
various conditions and with different combinations of stabilizers and found that it was 
possible to store dried vaccine at room temperature for up to 26 weeks without reducing 
the concentration of HA significantly. The main method for drying used in the study was 
a lyophilization based freeze-drying operation after the vaccine formulation was mixed 
with various stabilizers. The study found that drying resulted in changes to the secondary 
structure of the virus subunits and that drying with stabilizers helped to reduce the 
conformational change and aggregation introduced by drying. This was verified by using 
a circular dichroism analysis to measure changes in secondary protein structure. Mice 
given the dried/reconstituted samples showed no significant difference in immune 
response from the control group. One of the major findings of the study was that upon 
freezing of the vaccine, the pH of the vaccine began to change and thus induced a 
conformational change [21]. Another study was able to implement the aforementioned 
stabilizer based drying method with microneedle patches. This study was able to dry 
vaccine with various stabilizer and buffer combinations in microneedle patches, store 
them at temperatures up to 40°C for six months without any significant loss of HA 
activity. The mechanisms for the drying are not fully understood yet, but it was found 
that the excipients introduced while drying were able to create a matrix to replace the 
water that had been evaporated away and that this was able to keep the vaccine subunits 
from aggregating excessively and denaturing. The major benefit of using this method to 
increase thermal stability is that the dried vaccine does not need to be reconstituted before 
use because it is designed for use in soluble microneedles.  
 Once the microneedle is touched to the patient’s skin, the drug will reconstitute 
into the skin itself and deliver [9]. The two above mentioned studies lay the foundation for 
non-invasive thermo-stable microneedle delivery of influenza vaccine and have shown 
that the cold chain is not necessary if the proper conditions are met while drying. The 
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implications of the various studies mentioned above are that it is extremely difficult to 
create a thermo-stable formulation of the influenza vaccine. The major contenders are 
lyophilization, which is the method of choice in the medical industry at the moment, and 
microneedle patches that deliver dried/reconstituted vaccine. Lyophilization does not 
increase thermal stability in a long-term sense and introduces shear-mediated stresses on 
the vaccine, but is a means to an end. On the other hand, microneedles are painless, leave 
no hazardous waste, can be self-administered, and can retain thermal stability for much 
longer periods of time at much worse conditions of storage. They also have higher 
bioavailability when properly delivered past the stratum corneum. This makes 
microneedle delivery of influenza vaccine the method of choice when it comes to 
preference and the future applications are endless once the cold chain dependency of the 
vaccine is removed. 
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CHAPTER 3 
METHODS AND MATERIALS 
 
Vaccines and Excipients 
This study used both monovalent and trivalent vaccines. All monovalent vaccine used in 
this study was provided by Novartis Vaccines and Diagnostics (Cambridge, MA). 
Different strains of vaccine were used based on the type of storage condition and testing 
scenarios. For long-term storage, both monovalent and trivalent antigens from strains of 
[B/Brisbane/60/2008], [A/Brisbane/59/2007] (H1N1), and [A/Victoria/210/2009 (H3N2)] 
were used. For samples that were challenged with higher temperatures, 
[A/Brisbane/10/2010] (H1N1) antigens were used. All of the excipients employed were 
obtained from Sigma-Aldrich (St. Louis, MO). Vaccine/excipient methods were designed 
with Matthew J. Mistilis. 
 
Formulations and Buffer Exchanges 
All excipient based vaccine formulations were used at 10% w/v. Solution were prepared 
by dissolving the appropriate mass of excipient into a buffer solution. As mentioned 
earlier, certain samples required the use of different buffers for testing. Since stock 
vaccine was obtained in phosphate buffered saline (PBS), buffer exchanging was 
necessary. This was performed using Vivaspin 500, Vivaspin 20, or Vivaspin 2 
centrifuge filters with molecular weight cutoffs of 100, 10, and 3 kDa, respectively 
(Sartorius AG, Göttingen, Germany) to concentrate the vaccine to 10x or greater 
concentration followed by reconstitution in the desired buffer (usually 150 mM 
ammonium acetate buffer). All vaccine formulations also contained 1% w/v 




Using PDMS Chips for Drying Vaccine 
 In order to maintain a high throughput while testing samples, vaccine was dried 
on 6 mm diameter circular cutouts of polydimethylsiloxane (PDMS). PDMS was used in 
order to mimic the drying surface of a microneedle patch without having to make 
hundreds of patches. 2 µL droplets of vaccine were carefully pipetted onto the PDMS 
chips and weighed on a Sartorius SE2 Ultra Micro Balance (Sartorius AG, Göttingen, 
Germany) to account for pipetting inaccuracies. The drops were then allowed to dry and 
were stored at various conditions for stability testing in aluminum pouches (Oliver-Tolas 
Healthcare, Grand Rapids, MI) that were impulse heat-sealed (AIE-300, American 
International Electric, Industry, CA) and stored with desiccant. Once storage was 
complete, the chips were placed into plastic, 0.5, 2, or 5 mL tubes (depending on the 
volume of the solution) with a known volume of the same buffer that the vaccine dried in, 
allowing for the dried vaccine/excipient solution to reconstitute. A similar procedure was 
used for stainless steel microneedles, with the only difference being that stainless steel 
cutouts were used in place of the PDMS chips. PDMS chips methods were designed with 
Matthew J. Mistilis. 
 
Microneedle Patches 
 This study did not test full stainless steel microneedle patches, but soluble 
microneedle patches were tested. The procedure for making the microneedle patches 
consisted of adding the vaccine and sealing the mold with a backing. Vaccine was placed 
onto a premade microneedle patch mold and was pulled into the holes under vacuum. 
Excess vaccine that did not make it into the holes was removed using a flat blade. Once 
the vaccine solution dried in the mold, a polymer backing was added to seal the holes. 
The backing was made of a solution of polyvinyl alcohol, sucrose, and water in a mass 
ratio of 8:6:15. The patch molds were then dried for two days with desiccant after which 
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they were demolded using scotch tape. After demolding, the patches were stored and 
reconstituted in the same manner as the chips as described above. Patch fabrication 
methods were designed with Matthew J. Mistilis. 
 
ELISA 
 After reconstituting the chips/patches into buffer solutions, the solutions were 
assayed using a standard sandwich enzyme linked immunosorbent assay (ELISA) to test 
for active HA content. Polyclonal, strain-specific antibodies were received from the 
Center for Biologics Evaluation and Research of the Food and Drug Administration 
(Silver Spring, MD). Antibodies were conjugated to horseradish peroxidase with a 
Lightning Link conjugation kit (Innova Biosciences, Cambridge, UK). Unformulated 
vaccine stock was serially diluted in phosphate-buffered saline with 0.5% Tween-20 
(PBST) and used as a reference standard curve. An Immulon 2HB 96-well microplate 
(Thermo Scientific, Waltham, MA) was used as the coated surface. The microplate was 
washed 3 times between each step with PBST with 3% w/v bovine serum albumin. The 
HRP substrate reaction involved SureBlue Reserve TMB solution (KPL, Gaithersburg, 
MD), which was stopped with TMB Stop Solution (KPL). The microplate absorbance at 
620 nm was read using an iMark plate reader (BioRad, Hercules, CA). The standard 
curve was fit to a four-parameter function using the Microplate Manager 6 software 





 The results from this study are all centered on vaccine activity remaining after 
changing some part of the formulation or storage of a formulation. The major parameters 
tested were buffer solutions, surfactants, excipient stabilizer solutions, storage 
temperature, and patch performance. 
 
 
Figure 1. Activity of samples that were buffer exchanged and dried on PDMS chips at 
various temperatures. Some buffers were able to retain activity even at higher 
temperatures. Data represent averages of n = 6 replicates, with standard deviation bars 




Figure 2. Effects of various surfactants on vaccine stability and comparison of PDMS as 
drying surface with a stainless steel surface. Surfactant was added to liquid vaccine, 
which was dried on chips for 20 minutes at room temperature. Most surfactants did not 
significantly affect activity retention in the short term. Data represent averages of n = 6 




Figure 3. A screen of various stabilizers and their effects on vaccine activity after drying 
and storage at room temperature for 24 hours. All excipients were used at 15% w/v. *p-
value ≤ 0.05 when compared to vaccine with no added stabilizer. The light gray bar on 
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the far right is unformulated vaccine. Data represent averages of n = 6 replicates, with 
standard deviation bars shown. This data was obtained with Matthew J. Mistilis. 
 
 




Figure 4. Effects of combining lactose with a second stabilizer, either sorbitol or 
maltodextrin on vaccine activity. Data represent averages of n = 6 replicates, with 
standard deviation bars shown. This data was obtained with Matthew J. Mistilis. 
 
 
 Figure 5. Effects of stabilizer combinations on vaccine activity as opposed to using only 
one excipient at a time. Certain stabilizer combinations were statistically stable on PDMS 
chips for up to 1 month at 40°C. Asterisks (*) represent formulations which showed no 
statistical difference among the time points tested (Student’s t-test; p≤0.05). MB stands 
for monobulk vaccine, which is vaccine that was left without added stabilizer as a 
control. Data represent averages of n = 6 replicates, with standard deviation bars shown. 




Figure 6. Vaccine activity after storage in microneedle patches at 25°C for up to 6 
months. Patches were loaded with almost a full human dose of vaccine. (full human dose 
= 15 µg per strain) and three different strains of vaccine antigens were tested. The 
excipient combinations that were tested were the highest performers in Figure 3. 
Asterisks (*) represent formulations which showed statistically different activity between 
0 month and 6 month time points (Student’s t-test; p≤0.05). Data represent averages of n 






The results obtained from this study indicate that influenza vaccine can 
successfully be made thermally stable if formulated with an optimal combination of 
conditions in amounts as large as a full human dose. The data also closely matches the 
trends seen in stability testing during lyophilization. 
Analysis of the effects of buffer solutions on activity revealed that ammonium 
acetate was the optimal buffer for activity retention, with vaccine activity unaffected even 
after storage at 40°C, as seen in Figure 1. This is why many of the formulations that were 
tested were buffer exchanged from their stock PBS to ammonium acetate. The 
mechanism for stabilization via buffer salts is still being researched, but the current 
hypothesis is that certain salts within the buffer are more effective than others in keeping 
protein molecules from aggregating with each other. As for surfactants, many were useful 
for the initial coating/wetting of metal microneedles, but based on the data presented in 
Figure 2, none of them had positive effects on activity, regardless of the drying surface. 
Since surfactants were not found to be helpful during drying, and there is evidence that 
including surfactant in microneedle formulations can lead to instability during long-term 
storage, they were not included in any of the other microneedle patch formulations. They 
were also not necessary for the proper function of soluble microneedles, which were the 
focus of this study. 
A wide range of compounds were tested for possible stabilizing effects. After 
analyzing the excipient screen, it is clear that not all excipients had the same effect on 
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vaccine stability, but that there were several excipients able to maintain vaccine activity 
after drying. Of the stabilizers that were tested, there were several that improved stability 
(with respect to the vaccine without an added stabilizing excipient), but there were also a 
few that were detrimental to stability. Upon further testing, it was found that the activities 
in Figure 3 and Table 1 did not stay the same when samples were stored for longer 
periods of time. For this reason, combinations of stabilizers were tested alongside 
individual excipients. An example of one combination was when lactose was combined 
with two other stabilizers. Figure 4 shows that proper selection of the constituent 
stabilizers can actually yield a higher retention of activity than its constituent excipients 
(as well as a lower activity or an activity between the two constituents). Similar to the 
stabilizer screen in Figure 3, various combinations of the stabilizer combination were also 
tested, but this time at 40°C for up to one month of storage. The data for this is presented 
in Figure 5, and it is evident that certain combinations performed much better than others. 
Untreated vaccine was completely devoid of functional protein after one month of 
storage, but some of the combinations retained essentially 100% of their activity (no 
statistically significant difference). As controls, some of the high performing individual 
stabilizers were also tested, but were almost always outperformed by the combinations. 
 All of the previously mentioned data was obtained from dried vaccine on PDMS 
chips in an ammonium acetate buffer solution. As a further proof of concept, the vaccine 
was also incorporated into microneedle patches and assayed after production and storage. 
As seen in Figure 6, regardless of the strain of vaccine used, almost every excipient 
solution tested had no statistically significant difference between the vaccine at the day of 
drying and the vaccine six months later after storage at 25°C. Furthermore, the patches 
used a significantly larger volume of vaccine than the PDMS chips, and a full human 
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dose equivalent was loaded. This shows that the vaccine was effectively made thermally 
stable in the limits of a full human dose. 
 The implications of these results are that a proof of concept has been tested and 
proven for the stabilization of influenza vaccine for delivery via soluble microneedle 
patches. This technology holds the potential to reformat the administration of traditional 
vaccines and can also help remove many drug solutions from cold chain dependency. 
Hopefully, by making vaccination easier, more cost effective, and more accessible, this 
study’s broader aim is to reduce the prevalence of sickness and deaths that are 





 Influenza is responsible for several thousands of deaths around the world each 
year, yet is also one of the most preventable pathogenic infections. By receiving an 
influenza vaccination once per year, chances of death can be reduced by up to 70%. 
Currently, the clinical methods for vaccination involve the use of a hypodermic needle 
and syringe or an intranasal mist, both of which are severely limited with regards to ease 
of administration and maintaining vaccine integrity. A novel alternative to these methods 
is the use of microneedle patches with excipient stabilization, which allow for enhanced 
vaccine thermal stabilization as well as painless administration, reduced biohazardous 
sharps waste, potential self-administration, and high immunogenicity.  
 The results of this study have shown that finding the optimal combination of 
vaccines, excipients, buffers, and surfactants can lead to a stabilized, microneedle 
incorporated delivery system. Using an ammonium acetate buffer with excipients 
solutions containing combinations of trehalose, arginine, sucrose, and heptagluconate has 
been shown to stabilize and retain the activity of a full human dose of influenza vaccine 
for over six months at room temperature. Combinations of stabilizers were found to 
stabilize vaccines in a much different manner than individual excipients, with the 
frontrunners being formulations that contained at least two excipients. This study is one 
of many first steps in development of this technology, and the hope is that it will serve as 





 Plans for continuing research include using dynamic light scattering (DLS) and 
circular dichroism (CD) to monitor the mechanism of vaccine activity loss, as well as 
performing an animal study to verify in vivo immunogenicity. DLS is used to test for the 
size of particles in solution. Since influenza vaccine proteins tend to aggregate during 
drying, DLS can be used to better understand the mechanisms behind protein aggregation 
and denaturation. CD is useful for analyzing secondary protein structure. By following 
the changes in the arrangement of peptide chains in the HA protein, the mechanism of 
any protein conformational changes can be observed. Finally, an animal study utilizing 
mice is currently in progress. Mice are immunized either by standard vaccine via a 
syringe or by vaccine in a microneedle patch (some microneedle patches have been 
stored for various amounts of time). Antibody titers will be collected afterwards to 
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